Zongru Li

Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial

Qian Jiang, Zongru Li, Ya‐Zhen Qin et al. · Journal of Hematology & Oncology · 2022 · 99 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +11

Clinical features and long-term outcomes of interstitial lung disease with anti-neutrophil cytoplasmic antibody

Xin Sun, Min Peng, Ting Zhang et al. · BMC Pulmonary Medicine · 2021 · 39 citations · Full text

Medicine, Internal Medicine, Pathology +10

Novel BCR-ABL1 Tyrosine Kinase Inhibitor (TKI) HQP1351 (Olverembatinib) Is Efficacious and Well Tolerated in Patients with T315I-Mutated Chronic Myeloid Leukemia (CML): Results of Pivotal (Phase II) Trials

Qian Jiang, Xiao‐Jun Huang, Zi Chen et al. · Blood · 2020 · 27 citations

Medicine, Oncology, Pharmacology +8

Variables associated with self-reported anxiety and depression symptoms in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy

Dayu Shi, Zongru Li, Yongjie Li et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2020 · 19 citations

Social Sciences, Oncology, Psychology +15

Interaction+: Interaction enhancement for web-based visualizations

Min Lu, Jie Liang, Yu Zhang et al. · 2017 · 16 citations

Computing, Visualization, Data Visualization +14